Beyond Air Inc (OQ:XAIR)

Business Focus: Medical Equipment, Supplies & Distribution

May 01, 2024 07:00 am ET
Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting
Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced being selected to present on the clinical development program of its...
Mar 20, 2024 09:00 am ET
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients...
Feb 12, 2024 04:05 pm ET
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients...
Jan 18, 2024 08:00 am ET
Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients...
Dec 27, 2023 07:30 am ET
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) and a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that the Phase 1 Study...
Dec 20, 2023 08:31 am ET
Thinking about buying stock in Beyond Air, bluebird bio, Riot Platforms, Autolus Therapeutics, or Forge Global Holdings?
NEW YORK, Dec. 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XAIR, BLUE, RIOT, AUTL, and FRGE.
Dec 20, 2023 08:31 am ET
Thinking about buying stock in Polished.Com, Mereo BioPharma, Fusion Pharmaceuticals, Luminar Technologies, or Beyond Air?
NEW YORK, Dec. 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for POL, MREO, FUSN, LAZR, and XAIR.
Nov 15, 2023 04:05 pm ET
Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering...
Nov 14, 2023 08:31 am ET
Thinking about buying stock in Invo Bioscience, Singing Machine Company, Beauty Health, Beyond Air, or Tivic Health Systems?
NEW YORK, Nov. 14, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INVO, MICS, SKIN, XAIR, and TIVC.
Nov 13, 2023 04:05 pm ET
Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients...
Nov 03, 2023 12:00 pm ET
Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced encouraging first-in-human and first-in-class clinical...
Oct 19, 2023 04:05 pm ET
Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering...
Oct 17, 2023 04:05 pm ET
Beyond Air® To Participate in the Truist Securities BioPharma Symposium
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering...
Oct 17, 2023 07:30 am ET
Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Surviva
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announced today the publication of pre-clinical data demonstrating that...
Oct 16, 2023 07:30 am ET
Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conferen
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced promising new preclinical data further supporting the...
Oct 16, 2023 07:00 am ET
Beyond Air® Receives Innovative Technology Contract from Vizient for LungFit®PH
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients...
Oct 04, 2023 07:30 am ET
Beyond Cancer™ Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that Beyond Cancer, Ltd. will present two proffered...
Oct 02, 2023 04:05 pm ET
Beyond Air® To Participate in the Roth MKM 2023 Healthcare Opportunities Conference
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering...
Sep 27, 2023 09:00 am ET
Beyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting
Beyond Cancer, Ltd. (the “Company”), an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that the Company will present data at the...
Sep 18, 2023 04:05 pm ET
Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering...
Sep 07, 2023 07:30 am ET
Beyond Air® and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients...
Sep 06, 2023 07:00 am ET
Beyond Air® To Participate in the 2023 Cantor Global Healthcare Conference
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering...
Aug 10, 2023 04:05 pm ET
Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2024
Reported commercial sales for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Currently have in excess of $1 million in annual commercial LungFit PH contracts Secured up to $40 million in debt...
Aug 07, 2023 04:05 pm ET
Beyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD)
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering...
Aug 01, 2023 04:05 pm ET
Beyond Air® To Participate in BTIG’s 2023 Virtual Biotechnology Conference
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering...
Jul 24, 2023 04:05 pm ET
Beyond Air® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering...
Jun 22, 2023 04:05 pm ET
Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering...
Jun 15, 2023 04:10 pm ET
Beyond Air® Secures up to $40 Million Debt Financing
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including...
Jun 15, 2023 04:05 pm ET
Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients...
May 16, 2023 04:05 pm ET
Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Apr 19, 2023 09:00 am ET
Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced promising new in vivo and in vitro data that support the...
Mar 23, 2023 04:05 pm ET
Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including...
Mar 14, 2023 04:35 pm ET
Beyond Cancer™ to Present Two Posters for Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2023 AACR Annual Meeting
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that Beyond Cancer, Ltd. will present two posters at the...
Feb 22, 2023 07:00 am ET
Beyond Air® Announces Participation at Two Upcoming Investor Conferences in March 2023
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including...
Feb 09, 2023 04:05 pm ET
Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2023
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including...
Jan 30, 2023 07:00 am ET
Beyond Cancer® Appoints Gavin Choy, PharmD as Chief Operating Officer
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announced today the appointment of Gavin Choy, PharmD as Chief Operating...
Jan 24, 2023 04:05 pm ET
Beyond Cancer® Announces Sponsored Research Agreement with Stanford and Appointment of Frederick M. Dirbas, MD and Mark D. Pegram, MD to Scientific Advisory Board
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announces entry into a sponsored research agreement with Stanford School...
Jan 17, 2023 04:05 pm ET
Beyond Air® Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Dec 13, 2022 09:25 am ET
Beyond Cancer® Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that P
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, announced today the publication of pre-clinical data demonstrating...
Nov 17, 2022 04:05 pm ET
Beyond Air® To Participate in Piper’s 34th Annual Healthcare Conference
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension,...
Nov 10, 2022 09:00 am ET
Beyond Cancer™ Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced promising new in vivo combination data that support...
Nov 08, 2022 04:05 pm ET
Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023
Beyond Air, Inc. (NASDAQ: XAIR) a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension,...
Oct 24, 2022 07:30 am ET
Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension,...
Oct 20, 2022 04:05 pm ET
Beyond Air® Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension,...
Oct 17, 2022 04:05 pm ET
Beyond Air® Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit® GO at the CHEST Annual Meeting 2022
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension,...
Oct 05, 2022 08:00 am ET
Beyond Cancer™ to Present Pre-Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2022 SITC Annual Meeting
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that the Company will present data at the upcoming...
Oct 03, 2022 07:30 am ET
Beyond Air® Announces that Annals of the American Thoracic Society Published a Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension,...
Sep 16, 2022 04:05 pm ET
Beyond Air® To Participate in Three Upcoming Investor Conferences
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension,...
Aug 23, 2022 08:00 am ET
Beyond Air® Affiliate Beyond Cancer™ Doses Initial Patient in First-in-Human Phase 1 Study of Ultra-High Concentration Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov)
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that the first patient was treated in a first-in-human...
Aug 11, 2022 04:05 pm ET
Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2023
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension,...
Jul 27, 2022 04:05 pm ET
Beyond Air® Schedules First Fiscal Quarter 2023 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension,...
Jun 28, 2022 04:10 pm ET
Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Jun 28, 2022 04:05 pm ET
Beyond Air’s LungFit® PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Jun 14, 2022 04:30 pm ET
Beyond Air® Announces Fiscal Year End 2022 Financial Results Conference Call and Webcast Moved to Tuesday, June 28th
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Jun 01, 2022 07:00 am ET
Beyond Cancer™ Announces the Appointment of Jedidiah Monson, M.D. to Chief Medical Officer
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Jedidiah Monson, M.D. to the...
May 17, 2022 04:05 pm ET
Beyond Air® Presents Positive Study Update from the At-Home LungFit® GO Pilot Study for Nontuberculous Mycobacterial Lung Disease at the American Thoracic Society International Conference 2022
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
May 17, 2022 07:00 am ET
Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Susan Howell Jones, CPA as Chief...
May 16, 2022 07:05 am ET
Beyond Air® Schedules Fiscal Year 2022 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Apr 25, 2022 04:05 pm ET
Beyond Air® Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Apr 25, 2022 07:00 am ET
Beyond Air® Presents Positive Safety and Efficacy Data for Inhaled Nitric Oxide to Treat COVID-19 at ECCMID 2022
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Apr 18, 2022 07:00 am ET
Beyond Air® to Participate in Three Upcoming Medical Conferences
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Apr 11, 2022 07:00 am ET
Beyond Cancer™ Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Showing Ultra-High Concentration Nitric Oxide Therapy Anti-Tumor Effect
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced promising new in vivo and in vitro data that support...
Mar 08, 2022 04:35 pm ET
Beyond Cancer™ to Present Two Abstracts for Ultra-High Concentration Nitric Oxide Therapy at the 2022 AACR Annual Meeting
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Feb 10, 2022 04:05 pm ET
Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2022
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Feb 08, 2022 08:00 am ET
Beyond Air® Announces Participation at Upcoming Investor Conferences in March 2022
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Feb 03, 2022 04:05 pm ET
Beyond Air® Announces Two Appointments to Beyond Cancer™ Board of Directors
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Jan 27, 2022 08:00 am ET
Beyond Air® Schedules Third Fiscal Quarter 2022 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Dec 09, 2021 08:30 am ET
Beyond Air® Provides Regulatory Update for LungFit® PH
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Dec 01, 2021 08:00 am ET
Beyond Air® Expands Leadership Team with the Appointment of Dr. Andrew Colin to Chief Medical Officer
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Nov 29, 2021 08:31 am ET
Thinking about buying stock in Applied DNA Sciences, Co-Diagnostics, Precipio, Beyond Air, or Chembio Diagnostics?
NEW YORK, Nov. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APDN, CODX, PRPO, XAIR, and CEMI.
Nov 18, 2021 04:05 pm ET
Beyond Air® Announces $30 Million of Committed Capital in Previously Reported Beyond Cancer™ Private Placement
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Nov 11, 2021 04:05 pm ET
Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2022
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Nov 04, 2021 07:30 am ET
Beyond Air® Announces Formation of Beyond Cancer™, a New Private Company Dedicated to Oncology Utilizing Ultra-High Concentration Nitric Oxide to Treat Solid Tumors
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Nov 02, 2021 08:00 am ET
Beyond Air® to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Oct 25, 2021 08:00 am ET
Beyond Air® Schedules Second Fiscal Quarter 2022 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Oct 20, 2021 08:00 am ET
Beyond Air® Reports Positive Interim Results for LungFit® GO Pilot Study Using High Concentration Inhaled Nitric Oxide Self-Administered, At-Home for Nontuberculous Mycobacterial Lung Disease
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Sep 21, 2021 04:30 pm ET
Beyond Air® Provides Global Regulatory Update for LungFit® PH
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Sep 14, 2021 07:30 am ET
Beyond Air® to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Aug 20, 2021 04:15 pm ET
Beyond Air® Announces CFO Transition
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Aug 10, 2021 04:05 pm ET
Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2022
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Jul 22, 2021 08:30 am ET
Thinking about buying stock in Summit Wireless Technologies, Beyond Air, Clover Health, Waitr Holdings, or Kosmos Energy?
NEW YORK, July 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WISA, XAIR, CLOV, WTRH, and KOS.
Jul 20, 2021 07:30 am ET
Beyond Air® Schedules First Fiscal Quarter 2022 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Jul 08, 2021 04:14 pm ET
Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in July 2021
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Jun 10, 2021 04:05 pm ET
Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2021
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
May 26, 2021 07:30 am ET
Beyond Air® Reaches Settlement Agreement with Circassia for LungFit® PH
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
May 25, 2021 07:30 am ET
Beyond Air® Schedules Fiscal Year 2021 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
May 20, 2021 08:00 am ET
Beyond Air® Strengthens Commercial Leadership Team with Appointments of Head of Sales and Head of Marketing
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
May 13, 2021 08:00 am ET
Beyond Air® Presents Data in Hospitalized Patients with Viral Lung Infections (including COVID-19) from LungFit® PRO Programs at ATS 2021
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
May 03, 2021 08:00 am ET
Beyond Air® Appoints Peter Senior as Director of Business Development
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Apr 14, 2021 08:00 am ET
Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in May 2021
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Mar 24, 2021 08:00 am ET
Beyond Air® to Present Abstracts at the American Thoracic Society Virtual Sessions in May 2021
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric NO for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary...
Mar 01, 2021 08:00 am ET
Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in March 2021
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Feb 16, 2021 08:00 am ET
Beyond Air® Receives Grant for Up to $2.17 million from the Cystic Fibrosis Foundation to Advance the Clinical Development of Inhaled Nitric Oxide to Treat Nontuberculous Mycobacteria Pulmonary Diseas
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Feb 09, 2021 04:05 pm ET
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric NO for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary...
Jan 15, 2021 04:10 pm ET
Beyond Air® Schedules Third Fiscal Quarter 2021 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Dec 07, 2020 08:00 am ET
Beyond Air® Initiates Patient Screening for LungFit™ GO Pilot Study for At-Home, Self-Administration of Inhaled Nitric Oxide in Nontuberculous Mycobacteria Lung Disease
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Nov 19, 2020 08:00 am ET
Beyond Air® to Participate in the 32nd Annual Piper Sandler Healthcare Conference from December 1-3, 2020
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Nov 11, 2020 04:10 pm ET
Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Business Update
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Nov 11, 2020 07:30 am ET
Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Oct 23, 2020 08:00 am ET
Beyond Air® Schedules Second Fiscal Quarter 2021 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Oct 21, 2020 07:00 am ET
Beyond Air® Approved to Initiate Clinical Study at 150 ppm Nitric Oxide with LungFit™ for the Treatment of Acute Viral Pneumonia Including COVID-19
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Oct 19, 2020 10:01 am ET
Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR Conference on Tumor Immunology and Immunotherapy
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Oct 19, 2020 07:15 am ET
Beyond Air® Presents Data Showing Anti-Coronavirus Activity of Nitric Oxide at the CHEST Annual Meeting 2020
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Oct 19, 2020 07:00 am ET
Beyond Air® Presents Pilot Bronchiolitis Data at the CHEST Annual Meeting 2020
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Oct 16, 2020 08:00 am ET
Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Sep 30, 2020 08:00 am ET
Beyond Air® to Present Data on Nitric Oxide in the Treatment of Solid Tumors at the American Association for Cancer Research (AACR) Conference on Tumor Immunology and Immunotherapy
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Sep 11, 2020 08:00 am ET
Beyond Air to Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Sep 09, 2020 08:00 am ET
Beyond Air® to Present Posters on CoronaVirus and Bronchiolitis at the CHEST 2020 Annual Meeting
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Aug 27, 2020 08:00 am ET
Beyond Air® to Present New Nitric Oxide Data in an e-Poster Presentation at the North America Conference on Lung Cancer 2020 (NACLC 2020)
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Aug 10, 2020 04:01 pm ET
Beyond Air Publishes New Data on Nitric Oxide to Treat M. Abscessus in the Peer-Reviewed Journal Access Microbiology
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Aug 06, 2020 07:45 am ET
Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2021 and Provides Business Update
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Jul 23, 2020 08:00 am ET
Beyond Air® to Announce Fiscal First Quarter 2021 Financial Results on Thursday, August 6th
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Jun 22, 2020 04:01 pm ET
Beyond Air Reports Financial Results for Fiscal Fourth Quarter and Year-End 2020
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Jun 22, 2020 09:00 am ET
Beyond Air Announces Positive Preclinical Data Supporting High Concentration Nitric Oxide as a Potential Treatment for Solid Tumors
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Jun 15, 2020 08:30 am ET
Beyond Air Announces First Patient Enrolled in its U.S. Study of Nitric Oxide Therapy Using the LungFit™ System in COVID-19 Patients
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Jun 15, 2020 08:00 am ET
Beyond Air Announces Publication of Peer-Reviewed Journal Article in Scientific Reports
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Jun 08, 2020 05:30 pm ET
Beyond Air™ Scheduled to Announce Fiscal Year 2020 Financial Results on Monday, June 22nd
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
May 26, 2020 08:30 am ET
Beyond Air Receives Approval from Health Canada to Study Nitric Oxide Generated and Delivered by the LungFit™ in COVID-19 Patients
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
May 20, 2020 08:30 am ET
Beyond Air Achieves Primary Endpoint in Pilot Bronchiolitis Study
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
May 15, 2020 08:30 am ET
Beyond Air™ to Present New Data in an e-Poster Presentation at the Upcoming AACR Virtual Annual Meeting II on June 22nd to 24th
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
May 15, 2020 08:25 am ET
Beyond Air Enters into New Common Stock Purchase Agreement Extending Relationship with Lincoln Park Capital
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Apr 16, 2020 08:30 am ET
Beyond Air to Initiate Clinical Study Evaluating High Concentration Nitric Oxide for the Treatment of COVID-19 Patients in the United States
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...
Mar 18, 2020 08:30 am ET
Beyond Air Accelerates LungFit™ BRO COVID-19 Program
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, serious lung infections, including those...
Mar 16, 2020 08:00 am ET
Beyond Air Submits Investigational Device Exemption (IDE) to the United States Food and Drug Administration (FDA) for the Treatment of COVID-19 Patients
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including, serious lung infections and...
Mar 05, 2020 09:00 am ET
Beyond Air Hosting Analyst Day Today, March 5, 2020 at 2:00 p.m. ET
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including, serious lung infections and...
Feb 25, 2020 08:30 am ET
Beyond Air Hosting Analyst Day on March 5, 2020
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Feb 07, 2020 08:30 am ET
Beyond Air Reports Financial Results for Fiscal Third Quarter 2020
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Jan 22, 2020 08:00 am ET
Beyond AirTM Schedules Third Fiscal Quarter 2020 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Dec 18, 2019 04:03 pm ET
Beyond Air Terminates Commercial Licensing Agreement for LungFit™ PH for Use in the Hospital Setting in the United States and China
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Dec 12, 2019 04:15 pm ET
Beyond Air, Inc. Announces Closing of $11.5 Million Public Offering and Private Placement of Common Stock and Exercise of Option to Purchase Additional Shares
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Dec 10, 2019 09:12 am ET
Beyond Air Prices $10.5 Million Underwritten Offering of Common Stock and Concurrent Private Placement
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Dec 09, 2019 05:12 pm ET
Beyond Air Announces Proposed Public Offering and Concurrent Private Placement
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Nov 25, 2019 08:00 am ET
Beyond Air Signs Agreement with MESA Specialty Gases & Equipment for Nitric Oxide and Nitrogen Dioxide Calibration Gas Supply
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Nov 06, 2019 04:01 pm ET
Beyond Air™ Reports Financial Results for Fiscal Second Quarter 2020
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Nov 04, 2019 08:00 am ET
Beyond Air™ to Attend the American Association for Respiratory Care (AARC) 2019 Congress in New Orleans
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Oct 24, 2019 04:05 pm ET
Beyond Air™ Schedules Fiscal Second Quarter 2020 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Oct 22, 2019 04:30 pm ET
Beyond Air™ to Attend the American Academy of Pediatrics (AAP) National Conference and Exhibition in New Orleans
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Oct 16, 2019 08:00 am ET
Beyond Air™ Provides Update on High Concentration Nitric Oxide (NO) Animal Studies Using LungFit™
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Oct 01, 2019 04:05 pm ET
Beyond Air™ Presents Data at the 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Sep 23, 2019 04:25 pm ET
Beyond Air™ to Present at the Upcoming 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Sep 12, 2019 04:30 pm ET
Beyond Air™ to Participate at Two Upcoming Conferences
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Sep 03, 2019 04:59 pm ET
Beyond Air™ to Present at the 21st Annual H.C. Wainwright Global Investment Conference
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Aug 14, 2019 04:05 pm ET
Beyond Air™ Reports Financial Results for Fiscal First Quarter 2020
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Aug 05, 2019 08:00 am ET
Beyond Air™ Participating at the BTIG Biotechnology Conference on August 12
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Jul 30, 2019 08:00 am ET
Beyond Air™ Schedules First Fiscal Quarter 2020 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...
Jul 15, 2019 08:00 am ET
Beyond Air™ Announces New NASDAQ Ticker Symbol is XAIR
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.